SS
VRAX icon

Steve Schonfeld’s Virax Biolabs VRAX Stock Holding History

Steve Schonfeld’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-146
Closed -$115K – 3045
2022
Q3 		$115K Buy
+146
New +$241K ﹤0.01% 2513

Other funds holding VRAX

KI
Kapitalo Investimentos Sao Paulo, Brazil $1.58B AUM 19.49% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RAM
Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

Steve Schonfeld's VRAX Position: Q4 2022 in Review

Steve Schonfeld sold out of Virax Biolabs (VRAX) in Q4 2022, closing a stake of 146 shares — an estimated $115K sold.

Steve Schonfeld first reported a position in VRAX in Q3 2022 and held it in 1 quarter. The position peaked at $115K in Q3 2022. 7 funds tracked by Wall St. Rank hold VRAX as of Q4 2022.

  • Steve Schonfeld reported no remaining Virax Biolabs position as of Q4 2022 after selling out during the quarter.
  • Steve Schonfeld sold 146 Virax Biolabs shares in Q4 2022, an estimated $115K.
  • Steve Schonfeld first reported a position in Virax Biolabs in Q3 2022 and held it in 1 quarter.
  • Steve Schonfeld's Virax Biolabs position peaked at $115K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.